Novo Nordisk A/S (NYSE:NVO) on Monday said it has filed a lawsuit against telehealth company Hims & Hers Inc. (NYSE:HIMS) for infringing U.S. Patent 8,129,343 with Hims’ compounded semaglutide products for the U.S. market.

Novo Nordisk stock also gained momentum as it initiated the previously announced share repurchase program as part of the overall share repurchase program of up to 15 billion Danish kroner to be executed during 12 months beginning 4 February 2026.

Novo Nordisk’s Legal Move Explained

Novo Nordisk, in its press release, said Hims & Hers engaged in promotional campaigns that highlight its compounded semaglutide products, duping consumers and healthcare professionals as to the clinical benefits and safety of these unapproved drugs.

This includes Hims’ recent launch, and two days later, the